{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-211446","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.202473+00:00","generated_at":"2026-06-11T13:08:55.638474+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TherapeuticsMD Q2 net loss narrows to $2.4M as royalty transition continues","bullets":["Net loss from continuing ops of $2.4M ($0.24 per share) vs $14.9M ($1.70) in Q2 2022.","License and service revenue rose to $0.4M from $0.3M year-over-year, driven by Mayne License Agreement.","Total operating expenses fell 80.4% to $2.9M reflecting wind-down of manufacturing and commercial ops.","CEO says company is focused on cost reduction and cash conservation during ongoing business transformation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-211446","json":"https://secwatch.observer/filing/0001193125-23-211446.json","markdown":"https://secwatch.observer/filing/0001193125-23-211446.md","text":"https://secwatch.observer/filing/0001193125-23-211446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000119312523211446/0001193125-23-211446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000119312523211446/d513429d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T13:08:55.638474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"132efb16a856bc05dff2039eee8b98b3ea499b60","claim":"TherapeuticsMD, Inc. reported second quarter ended June 30, 2023 results: revenue $0.4 million, net income $2.4 million, EPS $(0.24) per basic and diluted common share.","evidence_excerpt":"License and service revenues from continuing operations, which are revenues related to license agreements, were $0.4 million for the quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000119312523211446/0001193125-23-211446-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$0.4 million"},{"label":"Net income","value":"$2.4 million"},{"label":"EPS","value":"$(0.24) per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}